WAVE Life Sciences PE Ratio 2014-2021 | WVE

Current and historical p/e ratio for WAVE Life Sciences (WVE) from 2014 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. WAVE Life Sciences PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

WAVE Life Sciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 5.15 0.00
2021-06-30 6.66 $-3.09 0.00
2021-03-31 5.61 $-3.46 0.00
2020-12-31 7.87 $-3.98 0.00
2020-09-30 8.49 $-5.04 0.00
2020-06-30 10.41 $-5.66 0.00
2020-03-31 9.37 $-5.73 0.00
2019-12-31 8.02 $-5.71 0.00
2019-09-30 20.53 $-5.35 0.00
2019-06-30 26.09 $-5.15 0.00
2019-03-31 38.85 $-5.16 0.00
2018-12-31 42.04 $-5.06 0.00
2018-09-30 50.00 $-4.86 0.00
2018-06-30 38.25 $-4.52 0.00
2018-03-31 40.10 $-4.21 0.00
2017-12-31 35.10 $-3.84 0.00
2017-09-30 21.75 $-3.54 0.00
2017-06-30 18.60 $-3.35 0.00
2017-03-31 27.50 $-2.94 0.00
2016-12-31 26.15 $-2.41 0.00
2016-09-30 32.47 $-2.09 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.261B $0.020B
WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00